Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 60

1.

Author Response: Rabies encephalitis presenting with new-onset refractory status epilepticus (NORSE).

Smith JH, Nuovo GJ, Villamar MF.

Neurol Clin Pract. 2018 Oct;8(5):371-372. doi: 10.1212/CPJ.0000000000000543. No abstract available.

PMID:
30564487
2.

Reader Response: Rabies encephalitis presenting with new-onset refractory status epilepticus (NORSE).

Jackson AC, Del Bigio MR.

Neurol Clin Pract. 2018 Oct;8(5):370-371. doi: 10.1212/CPJ.0000000000000542. No abstract available.

PMID:
30564485
3.

New onset refractory status epilepticus (NORSE).

Sculier C, Gaspard N.

Seizure. 2018 Sep 29. pii: S1059-1311(18)30192-4. doi: 10.1016/j.seizure.2018.09.018. [Epub ahead of print] Review.

PMID:
30482654
4.

NORSE Versus FIRES: What's in a Name?

Nickels K.

Epilepsy Curr. 2018 Sep-Oct;18(5):301-303. doi: 10.5698/1535-7597.18.5.301. No abstract available.

5.

Tocilizumab treatment for new onset refractory status epilepticus.

Jun JS, Lee ST, Kim R, Chu K, Lee SK.

Ann Neurol. 2018 Dec;84(6):940-945. doi: 10.1002/ana.25374. Epub 2018 Nov 30.

PMID:
30408233
6.

Unusual cause of fever, vision loss and super refractory status epilepticus in association with simian virus 40 (SV40).

Agarwal A, Vibha D, Chawla R, Sharma MC.

BMJ Case Rep. 2018 Oct 12;2018. pii: bcr-2018-225539. doi: 10.1136/bcr-2018-225539.

PMID:
30317196
7.

The Role of Hope, Compassion, and Uncertainty in Physicians' Reluctance to Initiate Palliative Care.

Wong NW.

AMA J Ethics. 2018 Aug 1;20(8):E782-786. doi: 10.1001/amajethics.2018.782.

8.

A favorable outcome of intensive immunotherapies for new-onset refractory status epilepticus (NORSE).

Kodama S, Arai N, Hagiwara A, Kimura A, Takeuchi S.

J Intensive Care. 2018 Jul 31;6:43. doi: 10.1186/s40560-018-0315-7. eCollection 2018.

9.

Jamestown Canyon encephalitis with NORSE and electrographic response to ribavirin: a case report.

Savard M, Paradis A, Francoeur CL.

Epilepsia Open. 2018 Apr 17;3(2):286-289. doi: 10.1002/epi4.12113. eCollection 2018 Jun.

10.

Updates in Refractory Status Epilepticus.

Marawar R, Basha M, Mahulikar A, Desai A, Suchdev K, Shah A.

Crit Care Res Pract. 2018 May 8;2018:9768949. doi: 10.1155/2018/9768949. eCollection 2018. Review.

11.

Febrile Infection-Related Epilepsy Syndrome (FIRES): An Overview of Treatment and Recent Patents.

Hon KL, Leung AKC, Torres AR.

Recent Pat Inflamm Allergy Drug Discov. 2018;12(2):128-135. doi: 10.2174/1872213X12666180508122450. Review.

PMID:
29745347
12.

Rabies encephalitis presenting with new-onset refractory status epilepticus (NORSE).

Villamar MF, Smith JH, Wilson D, Smith VD.

Neurol Clin Pract. 2017 Oct;7(5):421-424. doi: 10.1212/CPJ.0000000000000372. No abstract available.

13.

Extreme delta - With or without brushes: A potential surrogate marker of disease activity in anti-NMDA-receptor encephalitis.

Steriade C, Hantus S, Moosa ANV, Rae-Grant AD.

Clin Neurophysiol. 2018 Oct;129(10):2197-2204. doi: 10.1016/j.clinph.2018.02.130. Epub 2018 Mar 10.

PMID:
29580710
14.

New-onset refractory status epilepticus (NORSE) and febrile infection-related epilepsy syndrome (FIRES): State of the art and perspectives.

Gaspard N, Hirsch LJ, Sculier C, Loddenkemper T, van Baalen A, Lancrenon J, Emmery M, Specchio N, Farias-Moeller R, Wong N, Nabbout R.

Epilepsia. 2018 Apr;59(4):745-752. doi: 10.1111/epi.14022. Epub 2018 Feb 24. Review.

PMID:
29476535
15.

Proposed consensus definitions for new-onset refractory status epilepticus (NORSE), febrile infection-related epilepsy syndrome (FIRES), and related conditions.

Hirsch LJ, Gaspard N, van Baalen A, Nabbout R, Demeret S, Loddenkemper T, Navarro V, Specchio N, Lagae L, Rossetti AO, Hocker S, Gofton TE, Abend NS, Gilmore EJ, Hahn C, Khosravani H, Rosenow F, Trinka E.

Epilepsia. 2018 Apr;59(4):739-744. doi: 10.1111/epi.14016. Epub 2018 Feb 5. Review.

PMID:
29399791
16.

New-Onset Status Epilepticus in Pediatric Patients: Causes, Characteristics, and Outcomes.

Jafarpour S, Hodgeman RM, De Marchi Capeletto C, de Lima MTA, Kapur K, Tasker RC, Loddenkemper T.

Pediatr Neurol. 2018 Mar;80:61-69. doi: 10.1016/j.pediatrneurol.2017.11.016. Epub 2017 Dec 1.

PMID:
29373157
17.

A spicy status: Synthetic cannabinoid (spice) use and new-onset refractory status epilepticus-A case report and review of the literature.

Babi MA, Robinson CP, Maciel CB.

SAGE Open Med Case Rep. 2017 Dec 5;5:2050313X17745206. doi: 10.1177/2050313X17745206. eCollection 2017.

18.

New onset refractory status epilepticus due to primary angiitis of the central nervous system.

Matar RK, Alshamsan B, Alsaleh S, Alhindi H, Alahmedi KO, Khairy S, Baz S.

Epilepsy Behav Case Rep. 2017 Aug 19;8:100-104. doi: 10.1016/j.ebcr.2017.07.005. eCollection 2017.

19.

18F-FDG PET/MRI in cryptogenic new-onset refractory status epilepticus: a potential marker of disease location, activity and prognosis?

Nardetto L, Zoccarato M, Santelli L, Tiberio I, Cecchin D, Giometto B.

J Neurol Sci. 2017 Oct 15;381:100-102. doi: 10.1016/j.jns.2017.08.021. Epub 2017 Aug 17. No abstract available.

PMID:
28991656
20.

Cryptogenic NORSE: Its distinctive clinical features and response to immunotherapy.

Iizuka T, Kanazawa N, Kaneko J, Tominaga N, Nonoda Y, Hara A, Onozawa Y, Asari H, Hata T, Kaneko J, Yoshida K, Sugiura Y, Ugawa Y, Watanabe M, Tomita H, Kosakai A, Kaneko A, Ishima D, Kitamura E, Nishiyama K.

Neurol Neuroimmunol Neuroinflamm. 2017 Sep 25;4(6):e396. doi: 10.1212/NXI.0000000000000396. eCollection 2017 Nov.

Supplemental Content

Loading ...
Support Center